Develops gene therapies for rare skin diseases like dystrophic epidermolysis bullosa.
Jun 2026Revenue $440M/yrExpenses $243M/yr
Reached break-even Aug 2024
Figures by year
When did Krystal Biotech become profitable?
Its revenue passed its expenses in Aug 2024. In the 12 months to Jun 2026, revenue was $440M and expenses $243M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $389M | $228M | $161M |
| Dec 2024 | $291M | $225M | $65.7M |
| Dec 2023 | $50.7M | $160M | −$110M |
| Dec 2022 | $0.00 | $145M | −$145M |
| Dec 2021 | $0.00 | $68.3M | −$68.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.